This week on the podcast I interview Jacob Glanville, PhD we discuss Jacob's journey that led him to Distributed Bio then to Centivax and his work on the Netflix show Pandemic. Jacob Glanville is a serial entrepreneur and computational immuno-engineer. He built and sold his first company Distributed Bio from founding in March of 2012 to a 104M dollar sale to Charles River Laboratories in December of 2020. During that period, he developed the core business model, the research teams, and the technologies that enabled Distributed Bio to become profitable without investment. As part of the acquisition agreement, he founded Centivax Inc and spun out his assets in COVID-19 therapeutics, broad-spectrum vaccines, antivenom antibodies, anti-wound pathogen antibodies, anti-CXCR5 autoimmunity therapeutics, and blood-brain barrier translation technologies into Centivax, where he is now CEO.
Subscribe to Life Science Success for cutting-edge insights, expert interviews, and a vibrant community. Your subscription fuels our mission and keeps you at the forefront of life sciences.
